WO2018033939A1 - Procédé écologique industriel de fabrication du budésonide - Google Patents

Procédé écologique industriel de fabrication du budésonide Download PDF

Info

Publication number
WO2018033939A1
WO2018033939A1 PCT/IN2017/050350 IN2017050350W WO2018033939A1 WO 2018033939 A1 WO2018033939 A1 WO 2018033939A1 IN 2017050350 W IN2017050350 W IN 2017050350W WO 2018033939 A1 WO2018033939 A1 WO 2018033939A1
Authority
WO
WIPO (PCT)
Prior art keywords
budesonide
water
methylene dichloride
dioxane
reaction
Prior art date
Application number
PCT/IN2017/050350
Other languages
English (en)
Inventor
Anant THAKORE
Abhaykumar CHHEDA
Geeta Desai
Tejaskumar SHAH
Buchi Reddy Reguri
Rajashekhar CHIDURALA
Original Assignee
Avik Pharmaceutical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avik Pharmaceutical Limited filed Critical Avik Pharmaceutical Limited
Publication of WO2018033939A1 publication Critical patent/WO2018033939A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0092—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Definitions

  • the present invention relates to an improved process for the preparation of Budesonide on industrial scale. Particularly, the invention relates to improved process for the preparation of Budesonide using Perchloric acid catalyst in water medium.
  • Budesonide is designated chemically as (RS) 16a,17a-(Butylidenedioxy)-l ip,21- dihydroxypregna-l,4-diene-3,20-dione and having a structure of the following Formula-I.
  • Budesonide is generally known for the treatment of diseases which are associated with inflammation processes.
  • the active ingredient Budesonide has also been used successfully for the treatment of Inflammatory Bowel Disease and Irritable Bowel Syndrome including mild to moderate ulcerative colitis.
  • Budesonide and other structurally similar glucocorticoids were described for the first time in patent GB 1429922.
  • Budesonide is manufactured by reacting 16a-Hydroxy Prednisolone with n-Butyraldehyde in 1, 4-Dioxane in presence of Perchloric acid as a catalyst. This also needs multiple purifications and the crude is purified by column chromatography. Since the 1, 4-Dioxane is used in large quantities; it is projecting to effluent problems and complete recovery of solvent is leading to cost escalation to produce Budesonide.
  • US4835145 and US4695625 discloses a process for the preparation of 16,17-acetals of pregnane derivatives from corresponding 16, 17-acetonides by reaction with aldehydes in aqueous Hydrofluoric acid (HF) and Hydrochloric acid (HC1).
  • US6169178 also discloses a process for the preparation of Budesonide in the presence of aqueous Hydrobromic acid (HBr) and Hydroiodic acid (HI) as reaction catalysts and solvents.
  • HBr Hydrobromic acid
  • HI Hydroiodic acid
  • HI and HF acids are corrosive, light sensitive, expensive and these acids are environmental pollutants.
  • US5556964 discloses a process for the preparation of Budesonide by reacting 16a- Hydroxy prednisolone in acetonitrile in the presence of p-Toluene sulfonic acid as a catalyst. But this process also involved multiple purification methods increasing time cycle and production cost.
  • the present inventors have, surprisingly, found a novel process for preparation of Budesonide using Perchloric acid in water medium in good yields and purity.
  • the process of the present invention involves the use of water as medium along with small quantity of an organic solvent as a co-solvent thereby resulting in drastic minimization of formation of impurities, hence, with single purification, Budesonide obtained is conforming to EP-8.0/USP standards.
  • this process offers effluent having less COD, minimizes solvent usage and hence decreases recovery of solvent cost, thus improving the time cycle which is ultimately results in increase in productivity.
  • the co- solvent may be selected from 1,4-dioxane or Ethyl acetate. Accordingly in one aspect, the present invention provides an industrial process for preparation of Budesonide of the formula-I comprising;
  • the present invention provides a process for preparation of Budesonide of the formula-I comprising;
  • any of the words “including,” “includes,” “comprising,” and “comprises” mean “including without limitation” and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it.
  • Embodiments of the invention are not mutually exclusive, but may be implemented in various combinations.
  • the described embodiments of the invention and the disclosed examples are given for the purpose of illustration rather than limitation of the invention as set forth in the appended claims.
  • the present invention provides a process for preparation of Budesonide of the formula-I which comprises reacting 11 ⁇ , 16 ⁇ , 17 ⁇ , 21- tetrahydroxypregna-1, 4-diene-3, 20-dione (16a-Hydroxy Prednisolone) of Formula-II with n-Butyraldehyde using Perchloric acid in water medium in presence of small volume of co-solvent to obtain Budesonide.
  • the present invention provides a process for preparation of Budesonide of the formula-I which comprises reacting 16a-Hydroxy Prednisolone of formula-II with n-Butyraldehyde in water and a small quantity of 1,4-dioxane or ethyl acetate in the presence of Perchloric acid to obtain Budesonide.
  • water as solvent may be used in the range of 2 mL/gm to 10 mL/gm of substrate, 16a-Hydroxy Prednisolone. However, preferably about 5 mL water per gm of 16a-Hydroxy Prednisolone is used.
  • 1,4-dioxane or ethyl acetate solvent may be used as co solvent during the reaction in very small quantities. Quantity of 1,4-dioxane or ethyl acetate may vary from 0.25 mL to 1.5 mL per gm of 16a-Hydroxy Prednisolone used. However about 0.5 mL of 1,4-dioxane or ethyl acetate per gm of 16a-Hydroxy Prednisolone is preferred.
  • Prednisolone of formula-II and n-Butyraldehyde is taken in water and 1,4-dioxane or ethyl acetate is added under an inert atmosphere.
  • Perchloric acid is added to the reaction mixture at about 0°C and maintained the reaction at -5°C to 25°C temperature till completion of reaction. Usually reaction completes in 30 minutes to 150 minutes.
  • the product is isolated by conventional procedures such as drowning the mass in water and filtering to isolate the solids.
  • the solids are further dissolved in suitable solvent such as methylene dichloride, washed the solution with water.
  • the solution may be treated with charcoal before concentration to isolate crude.
  • the crude Budesonide is further purified from a mixture of methanol and isopropyl ether solvents to obtain purified Budesonide meeting the specifications of EP and USP in single purification.
  • the suspension was stirred for 30 minutes and filtered the mass.
  • the obtained wet cake was dissolved in methylene dichloride.
  • the aqueous filtrate was extracted twice with methylene dichloride and the extract was combined with methylene dichloride solution. The solution was washed with water till neutral pH.
  • the methylene dichloride layer was treated with activated carbon for 60 minutes and filtered through celite.
  • the filter cake was washed with methylene dichloride and the filtrate is concentrated under vacuum up to dryness to obtain crude Budesonide in solid form.
  • Epimer-A 42.2%
  • Epimer-B 57.7%
  • the wet cake of Budesonide (crude) was dissolved in 125 ml of methylene dichloride. After separation, the main aqueous layer was extracted twice with methylene dichloride and the extract was combined with methylene dichloride solution. The solution was washed with water till neutral pH.
  • the methylene dichloride layer was treated with activated carbon for 60 minutes and filtered through celite.
  • the filtered cake was washed with methylene dichloride and the filtrate is concentrated under vacuum up to dryness to obtain crude Budesonide in solid form.
  • the methylene dichloride layer was treated with activated carbon for 60 minutes and filtered through celite.
  • the filtered cake was washed with methylene dichloride and the filtrate is concentrated under vacuum up to dryness to obtain crude Budesonide in solid form.
  • the wet cake of Budesonide (crude) was dissolved in 3675 ml of methylene dichloride. After separation, the main aqueous layer was extracted twice with methylene dichloride and the extract was combined with methylene dichloride solution. The solution was washed with water till neutral pH.
  • the methylene dichloride layer was treated with activated carbon for 60 minutes and filtered through celite.
  • the filtered cake was washed with methylene dichloride and the filtrate is concentrated under vacuum up to dryness to obtain crude Budesonide in solid form.
  • the suspension was stirred for 30 minutes and filtered the mass.
  • the obtained wet cake was dissolved in methylene dichloride.
  • the main aqueous filtrate was extracted twice with methylene dichloride and the extract was combined with methylene dichloride solution. The solution was washed with water till neutral pH.
  • the methylene dichloride layer was treated with activated carbon for 60 minutes and filtered through celite.
  • the filter cake was washed with methylene dichloride and the filtrate is concentrated under vacuum up to dryness to obtain crude Budesonide in solid form.
  • Epimer-A 41.58%
  • Epimer-B 58.34%

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne un procédé amélioré pour la préparation du budésonide à l'aide d'un catalyseur acide perchlorique dans de l'eau utilisée comme milieu principal.
PCT/IN2017/050350 2016-08-16 2017-08-16 Procédé écologique industriel de fabrication du budésonide WO2018033939A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621027900 2016-08-16
IN201621027900 2016-08-16

Publications (1)

Publication Number Publication Date
WO2018033939A1 true WO2018033939A1 (fr) 2018-02-22

Family

ID=61196690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2017/050350 WO2018033939A1 (fr) 2016-08-16 2017-08-16 Procédé écologique industriel de fabrication du budésonide

Country Status (1)

Country Link
WO (1) WO2018033939A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0875516B1 (fr) * 1997-04-30 2005-10-12 Farmabios S.p.A. Préparation stéréospécifique en position C-22 des acétals-16,17 de pregnane
US20090259037A1 (en) * 2008-04-11 2009-10-15 Roberto Lenna Process for preparing budesonide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0875516B1 (fr) * 1997-04-30 2005-10-12 Farmabios S.p.A. Préparation stéréospécifique en position C-22 des acétals-16,17 de pregnane
US20090259037A1 (en) * 2008-04-11 2009-10-15 Roberto Lenna Process for preparing budesonide

Similar Documents

Publication Publication Date Title
US10112970B2 (en) Process for the preparation of 17-desoxy-corticosteroids
EP2817319B1 (fr) Nouveau procédé de préparation du ciclésonide
US7468433B2 (en) Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-dihydroxy-pregna-1,4-dien-3,20-dion or its 21-isobutyrat by transketalisation
WO2018033939A1 (fr) Procédé écologique industriel de fabrication du budésonide
EP2675820A1 (fr) Procédé de préparation amélioré du lévonorgestrel
EP2108653B2 (fr) Procédé de préparation de budésonide
CN106883227B (zh) 通过麦角菌发酵废料制备麦角新碱的方法
CN105367618A (zh) 氢化可的松的制备方法
JP2002155098A (ja) フルオロステロイド類の製造方法
CN110741006B (zh) 将粗子囊霉素转化为纯化的吡美莫司的方法
EP0994119B1 (fr) Procédé stereoselectif pour la préparation de l'épimer 22R de budesonide
CN113368115B (zh) 一种罗库溴铵的药物组合物以及罗库溴铵的精制方法
CN111320588B (zh) 一种纯化Lesinurad的方法
CN109485689B (zh) 小儿哮喘药布地奈德的制备方法
WO2007080463A1 (fr) Procede ameliore pour la preparation de dipyridamole
DE1131213B (de) Verfahren zur Herstellung neuer Pregnanverbindungen
CN117285593A (zh) 卡非佐米侧链的对映异构体去除方法和卡非佐米制备方法
US2831002A (en) delta4, 9(11)-pregnadienes
CN105294800A (zh) 一种醋酸氢化可的松的制备方法
CN115785188A (zh) 一种布地奈德的制备方法
EP1207165A2 (fr) Procédé d'isomérisation des 6.beta.-Fluorostéroides aux dérivés 6.alpha.- correspondants
CN117430653A (zh) 一种氢化可的松醋酸酯的制备方法
AU2002229536B2 (en) Process for the production of 16,17-[(cyclohexylmethylen)bis(oxy)]-11,21-Dihydroxy-pregna-1,4-dien-3,20-dion or its21-isobutyrat by transketalisation
CN114685591A (zh) C1,2位脱氢甾体化合物的精制方法和应用
NO136727B (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17841237

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17841237

Country of ref document: EP

Kind code of ref document: A1